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Viewpoint
The ethics of expanding access to cheaper, less eﬀ ective 
treatments
Govind C Persad, Ezekiel J Emanuel
In 1994, the US Food and Drug Administration (FDA) 
approved stavudine as a treatment for HIV/AIDS at 
40 mg twice a day. Stavudine quickly became standard 
care in high-income countries as part of highly active 
antiretroviral therapy (HAART).1 In 2006, WHO 
recommended using a lower dose of this drug (30 mg 
twice a day). Although eﬀ ective in reducing viral load, 
stavudine has serious side eﬀ ects including peripheral 
neuropathy, lactic acidosis, and lipodystrophy. An 
alternative drug zidovudine, also has serious side eﬀ ects 
such as anaemia, and is more expensive than stavudine. 
In 2001, the FDA approved tenofovir for treatment of 
HIV/AIDS. Concerned about the side eﬀ ects of stavudine 
and zidovudine, in 2013 WHO recommended tenofovir-
based antiretroviral therapy (ART) as the preferred option 
in low-income and middle-income countries. They 
recommended against using stavudine-based ART, but 
for decision makers to consider zidovudine if tenofovir 
was not available.2
In South Africa 6·8 million people have HIV. Of these, 
3·1 million are estimated to be receiving ART. Thus, 
according to WHO’s 2015 HIV treatment criteria, 
3·7 million South Africans are eligible for ART but are 
not receiving it.3 Because of the comparatively high cost 
of tenofovir and the millions of untreated patients, South 
African researchers proposed assessing low-dose 
stavudine (20 mg twice a day) as an alternative to 
tenofovir.4 However the proposal was controversial, with 
some researchers and advocates arguing that stavudine 
should never be used2 and others suggesting the use of 
cheaper stavudine early on in treatment before its side 
eﬀ ects are likely to develop and then later switching to 
more expensive treatments.1 Others have recommended 
continuing to use stavudine but monitoring for side 
eﬀ ects. Finally, some have suggested shifting to 
zidovudine, whose cost and toxic eﬀ ects are intermediate 
between tenofovir and stavudine. 
The choice between diﬀ erent HIV/AIDS drugs aﬀ ects 
millions of people. According to WHO’s 2015 
recommendations,3 all 35 million people with HIV 
worldwide should receive ART. Unfortunately, at most 
only 15 million patients with HIV are receiving ART.5 
According to UNAIDS, only 41% of all adults with HIV 
were receiving ART at the end of 2012.6 Current tenofovir-
based treatment costs an estimated US$150 per person 
per year for drugs alone, whereas stavudine-based 
therapy costs about $60 per person per year.7 At these 
prices, to transition just 15 million patients receiving 
stavudine-based ART to tenofovir would annually cost 
$1·35 billion. To cover all 20 million untreated HIV 
patients with tenofovir-based ART would cost an 
additional $3 billion. UNITAID has oﬀ ered $77 million 
to transition patients to tenofovir, but even this would 
only cover fewer than a million of such transitions.7
Similar questions arise regarding other diseases, such 
as whether to treat epilepsy with phenobarbital or pricier 
newer drugs,8 which antibiotics to prescribe for bacterial 
meningitis,9 whether to diagnose cervical dysplasia with 
the human papillomavirus (HPV) test or with acetic acid, 
and whether to approve the re-use of medical devices.10 
WHO has taken contrasting positions in diﬀ erent cases. 
For example, WHO endorses the use of cheaper acetic 
acid rather than HPV tests in low-income countires, 
but rejects the re-use of medical devices in these 
same countries. 
These examples raise a fundamental question of justice 
in global health. Is it ethically preferable to provide a 
larger number of people with cheaper treatments that are 
less eﬀ ective (or more toxic), or to restrict treatments to a 
smaller group to provide a more expensive but more 
eﬀ ective or less toxic alternative? As WHO’s contrasting 
positions indicate, this debate has persisted unresolved.
This debate could be resolved by use of 
three foundational principles of justice: utility, equality, 
and priority for those worst oﬀ . These three principles 
favour expanding access to less eﬀ ective or more toxic 
treatments rather than requiring the worldwide best 
treatment in all settings. We selected these principles 
because the debate is a question of population-level 
ethics rather than personal or professional ethics, in 
which bioethical principles of autonomy, beneﬁ cence, 
and non-maleﬁ cence are typically invoked.
Utilitarian reasoning aims for the greatest good for the 
greatest number. In medical contexts, this reasoning 
means maximising the medical beneﬁ t per unit of money 
spent. Utilitarianism favours expanding access to low-
cost alternative drugs. Of course, in the decision between 
expansion of access to second-best treatments and a 
requirement that any treatment oﬀ ered be the best 
available, the details matter. Sometimes more expensive, 
more eﬀ ective interventions are more cost-eﬀ ective, or 
expansion of access to medical treatments from 90% to 
100% of people is very costly. However, if some people 
are receiving no treatment at all, expanding access will 
likely be the most cost-eﬀ ective option. 
The equality principle emphasises similar treatment 
for similar cases. Equality is typically invoked to support 
provision of a standard of care in low-income and middle-
income countries equal to that in high-income countries. 
Farmer and Gastineau contend that “eﬃ  ciency cannot 
trump equity in the ﬁ eld of health and human rights”.11 
However, this approach reduces inequality among 
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treated patients at the expense of causing far greater 
inequality between treated and untreated patients. When 
not enough funding is available to provide tenofovir-
based ART to all 35 million patients with HIV, a 
requirement that any care provided be the best available 
will leave millions untreated.9 Provision of cheaper, less 
eﬀ ective or more toxic treatment to many who would 
otherwise go untreated will better decrease inequality 
than provision of the best care to a few patients.
Finally, patients receiving no treatment are medically 
worst oﬀ , and highly likely to be worse oﬀ  in terms of 
overall justice, compared with those who receive treatment. 
To provide untreated patients with eﬀ ective treatment, 
albeit with additional toxic eﬀ ects, is a higher priority than 
to provide more eﬀ ective or safer treatments to patients 
already receiving eﬀ ective, if moderately toxic, treatments. 
As a previous WHO director, Gro Harlem Brundtland, 
stated, “if services are to be provided for all then not all 
services can be provided. The most cost-eﬀ ective services 
should be provided ﬁ rst”.12 
Objections have been raised against the approach of 
providing more people with less costly but less eﬀ ective or 
more toxic treatments. Some object that enough money is 
available to simultaneously expand access and improve 
eﬃ  cacy and safety. Obtaining that money is only a matter 
of will, not of overcoming scarcity.
The worldwide gross-domestic product is about 
$78 trillion, representing more than enough money to 
provide adequate care for everyone. Unfortunately, 
global health assistance has remained relatively ﬂ at 
since 2010,9 and the so-called golden age of growing 
global health assistance seems to have ended.9,12 Until 
additional funding can plausibly be identiﬁ ed and 
allocated, the principle that any care provided be the best 
available means that millions of people with HIV/AIDS, 
especially in sub-Saharan Africa, will remain untreated.
Even if the funds needed were available, whether 
HIV/AIDS should be the top global health priority is 
unclear. Currently, global assistance is $1·4 billion for 
tuberculosis, $2·4 billion for malaria, and $200 million 
for intestinal worms, schistosomiasis, and other 
neglected tropical diseases.12 The diﬀ erence in cost 
between provision of stavudine and of tenofovir to all 
eligible but currently untreated individuals greatly 
exceeds what is spent on tuberculosis and neglected 
tropical diseases worldwide.
Others claim that a requirement for all care provided to 
be the best available will reduce the cost of the best 
treatments. They cite the application of such 
requirements to previous HIV/AIDS treatments that 
forced down costs, asserting that reduced prices will 
allow everyone—in the long term—to be treated with the 
world’s best interventions.2,13
Whether requiring the expanded use of the world’s best 
treatments will lower their market prices is an empirical 
question,2,4 but there is no guarantee. The outcome 
depends on the treatment in question, the appeal of the 
patients to the public, the power of interest groups, media 
interest, and other factors. Furthermore, even if removal 
of the second-best treatment option did force down costs, 
because pharmaceutical companies would have to choose 
between reducing prices or leaving people untreated, it is 
manipulative to deny people treatment to pressure 
pharmaceutical companies to lower prices. Presumably, 
patients with HIV/AIDS might prefer stavudine-based 
ART to no ART. Even if some patients might refuse 
stavudine as a protest against pharmaceutical companies, 
this does not licence the endangerment of patients who 
did not consent to this strategy.
By contrast, many others object that providing less than 
the best available treatment wrongs patients. They 
contend that cheaper, less eﬀ ective treatments cause 
patients needless suﬀ ering and deprive them of what 
they are entitled to receive.2 Patients currently receiving 
tenofovir are entitled to continue receiving it. 
This objection ignores the suﬀ ering of patients who go 
untreated. To require that the standard of care in high-
income countries be used worldwide favours patients 
with HIV/AIDS and other diseases that exist in high-
income countries and creates a bias against improving 
care for patients in low-income and middle-income 
countries with diseases, such as malaria and parasites, 
which are rare in most high-income countries.14,15 To deny 
low-income and middle-income countries the opportunity 
to use cheaper treatments for HIV/AIDS and allocate the 
saved money to address health threats that are not 
prevalent in high-income countries makes no more sense 
than denying people who are ill access to a toxic but 
curative medicine on the basis that healthy people would 
refuse it. Additionally, global health actors must judge the 
needs of all, and not favour incumbent recipients of 
beneﬁ ts. Other services, such as disaster response teams, 
can be shifted from current beneﬁ ciaries to a more 
pressing challenge, and so too should availability of funds 
for medical interventions.
In conclusion, the provision of less eﬀ ective or more 
toxic interventions is justiﬁ ed by the principles of utility, 
equality, and priority for those worst-oﬀ . Advocates and 
WHO are mistaken to demand that medical care provided 
in low-income and middle-income countries should be 
the same as in high-income countries. Instead, expansion 
of access to treatments that are eﬀ ective, even if not the 
most eﬀ ective, should be the standard in global health.
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